Compare ANGI & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANGI | MYGN |
|---|---|---|
| Founded | 1995 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 551.9M | 625.5M |
| IPO Year | 2017 | 1995 |
| Metric | ANGI | MYGN |
|---|---|---|
| Price | $13.98 | $6.52 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 12 |
| Target Price | ★ $18.20 | $11.82 |
| AVG Volume (30 Days) | ★ 920.8K | 914.1K |
| Earning Date | 02-10-2026 | 02-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 13.43 | N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | ★ $1,057,636,000.00 | $825,300,000.00 |
| Revenue This Year | N/A | $0.08 |
| Revenue Next Year | $3.41 | $5.28 |
| P/E Ratio | $19.62 | ★ N/A |
| Revenue Growth | N/A | ★ 0.21 |
| 52 Week Low | $10.25 | $3.76 |
| 52 Week High | $20.70 | $15.47 |
| Indicator | ANGI | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 63.22 | 45.83 |
| Support Level | $12.23 | $6.09 |
| Resistance Level | $14.58 | $6.85 |
| Average True Range (ATR) | 0.57 | 0.25 |
| MACD | 0.11 | 0.03 |
| Stochastic Oscillator | 74.78 | 54.66 |
Angi Inc connects quality home service professionals with consumers across different categories, from repairing and remodeling to cleaning and landscaping. It operates through brands like Angi, HomeAdvisor, and Handy. The company has three operating segments, namely, Ads and Leads, Services, and International (Europe and Canada). A majority of its revenue is generated from the Ads and Leads segment, which provides professionals the capability to engage with potential customers, including quoting and invoicing services, and provides consumers with tools and resources to help them find professionals nationwide for home repair, maintenance, and improvement projects. Geographically, the company derives its key revenue from the United States and also has a presence in other countries.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.